Eye drop de­vel­op­er Oculis show­cas­es pos­i­tive PhII da­ta; Aque­s­tive hunts for an­oth­er FDA OK

→ Oph­thal­mol­o­gy-fo­cused Swiss drug de­vel­op­er Oculis has rolled out pos­i­tive da­ta from their Phase II study of OCS-01 — an eye drop for­mu­la­tion of dex­am­etha­sone for the treat­ment of di­a­bet­ic mac­u­lar ede­ma (DME). The study met its pre-de­fined ef­fi­ca­cy end­points and showed that OCS-01 eye drops were more ef­fec­tive than the ve­hi­cle in di­min­ish­ing cen­tral mac­u­lar thick­ness and im­prov­ing acu­ity in pa­tients with DME.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER